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To guide selection of carbapenems or fourth-generation cepha-
losporins as therapy, 110 Klebsiella pneumoniae isolates with
extended-spectrum β -lactamases from Taiwan were character-
ized by phenotypic (MICs), molecular, and chemical methods.
MIC patterns of ceftazidime and cefepime clearly differentiate
strains treatable by cefepime and those capable of efficiently
hydrolyzing available cephalosporins (CTX-M series and SHV-
types). Continued use of cefepime appears to be a treatment
option in cases for which MIC results are available and inter-
preted by the criteria presented. 
n recent years, extended-spectrum β -lactamase-producing
Klebsiella pneumoniae (ESBL-KP) strains of the TEM,
SHV, and CTX-M types have been discovered worldwide.
Reference broth microdilution susceptibility rates (MIC <8
mg/L) for cefepime among ESBL-KP in various geographic
regions show a wide range: Canada 94.4%, United States
87.6%, Western Pacific 76.1%, Europe 63.6%, and Latin
America 49.6% (1). In Taiwan, the in vitro cefepime suscepti-
bilities of ESBL-KP ranged from 37% to 100% (2,3). The
gene encoding SHV-5 (pI 8.2) has been reported to be the most
common ESBL in klebsiellae in Taiwan (2,4). The CTX-M-3
(pI 8.4) enzyme has also been discovered in Escherichia coli
isolates in southern Taiwan (5). For our study, we focused on
the mechanisms of cefepime resistance among ESBL-KP iso-
lates in Taiwan and attempted to predict cephalosporin thera-
peutic potentials by simple phenotypic patterns.
The Study
We initially conducted reference broth microdilution tests
(6,7) for 211 isolates of endemic and epidemic ESBL-KP from
Taiwan; 53% of isolates had a cefepime MIC of <8 mg/L (sus-
ceptible). Isoelectric focusing (IEF) was then performed by the
method of Matthew et al. (8). Approximately 40% of isolates
had an enzyme with a pI of 8.2 (SHV-5); 40% of isolates pro-
duced enzymes with a pI of 7.9, 8.4, or 8.8 (CTX-M-type); an
additional 20% of isolates contained both an SHV-5 plus a
CTX-M enzyme. 
The IEF results of 110 geographically representative iso-
lates of ESBL-KP were categorized by cefepime MIC level
(Table). The enzymes with pIs of 7.6 and 5.4 were SHV-1 and
TEM-1, respectively, which have been reported previously in
Taiwan hospitals (2,4). All the enzymes with pIs of 5.4, 7.6,
and 8.2 were evenly distributed among the isolates regardless
of cefepime MIC values, indicating no association with resis-
tance to this fourth-generation cephalosporin. All 23 isolates
with pI 8.2 enzymes and a nonsusceptible cefepime MIC (>16
mg/L) contained enzymes with pIs of 7.9, 8.4, or 8.8. In the
absence of these CTX-M enzymes, isolates with pI 8.2
enzymes remained susceptible to cefepime. Thus, the high
MIC level for cefepime was attributed to enzymes with pIs of
7.9, 8.4, and 8.8. This finding is supported by the fact that
those isolates with a single CTX-M enzyme (10 with pI 7.9
enzymes [CTX-M-14] and 8 with pI 8.4 enzymes [CTX-M-3])
had very elevated cefepime MIC results in the absence of a pI
8.2 enzyme (9). Two isolates with pI 8.4 enzymes remained
susceptible to cefepime (MIC 2 µg/mL) and probably pro-
duced low levels of CTX-M-3. 
These data indicate that cefepime resistance in ESBL-KP
isolates from Taiwan may result from either the cumulative
effect of pI 7.9, 8.4, 8.8, or 8.2 enzymes or hyperproduction of
any of the enzymes with the CTX-M phenotype (pI 7.9, 8.4, or
8.8). The enzyme with a pI of 8.8 is a novel CTX-M β -lacta-
mase most similar to CTX-M-3 (9). 
Several CTX-M enzymes have been shown to confer high
MIC levels for cefepime (10-12). Bauernfeind et al. reported
an isolate of Salmonella Typhimurium that had a CTX-M-2
enzyme (pI 7.9) and a cefepime MIC of 64 mg/L (10). Out-
breaks have also been reported of isolates producing CTX-M
enzymes (pI 8.4), including K. pneumoniae (cefepime MIC 4-
8 mg/L), E. coli (cefepime MIC 8-32 mg/L), and Serratia
marcescens (cefepime MIC 16-64 mg/L) (11). 
Szabo et al. reported an outbreak of 14 ESBL-KP strains
(pI 8.2, probably SHV-5) that had high-level resistance to
cefepime (MIC90 >256 mg/L) (12). Tzouvelekis et al. also
noticed seven isolates of ESBL-KP (SHV-5) with cefepime
MICs ranging from 32 mg/L to 64 mg/L. These researchers
described the elevated cefepime MIC as being due to the com-
bined effect of SHV-5 hyperproduction and decreased outer
membrane permeability (loss of 36-kDa outer membrane pro-
tein [OMP]) (13). The cefepime MIC for isolates hyperproduc-
ing SHV-5 without loss of the 36-kDa OMP remained <16 mg/
L, a susceptible level (13). Loss of the 36-kDa OMP also con-
ferred cefoxitin resistance, and introduction of a plasmid car-
rying the 36-kDa OMP gene markedly reduced the MIC of
cefoxitin, from 128 mg/L to 16 mg/L (13). Whether the iso-
lates reported by Szabo et al. also had concomitant outer mem-
brane defects is unknown, but these authors later
recommended that cefepime not be considered the treatment of
choice against SHV-5-producing ESBL-KP (14). Whether our
cefepime-resistant isolates had a concomitant OMP defect is
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similarly unknown. However, in 44 isolates with cefepime
MICs >16 mg/L, only 7 were resistant to cefoxitin. Further-
more, for isolates with high cefepime MIC values resulting
from single CTX-M enzymes (10 with pI 7.9 and 8 with pIs of
8.4), only two (one each with pIs of 7.9 and 8.4) were resistant
to cefoxitin. The relatively low rates of cefoxitin coresistance
provide indirect evidence that 36-kDa OMP loss may not play
an important role in the expression of cefepime resistance in
ESBL-KP strains in Taiwan. 
Conclusions
Alternative therapy using cefepime against ESBL-KP
strains in Taiwan could be reliable if appropriately guided by
cefepime and ceftazidime MIC results. The cefepime MIC is
useful for predicting the presence of CTX-M enzymes, which
usually confer resistance to this fourth-generation cepha-
losporin. Cefepime cannot be used if the MIC exceeds 8 mg/L,
which predicts the presence of CTX-M β -lactamases.
Cefepime may reasonably be used clinically if the MIC is con-
sistently <1 mg/L, which indicates the absence of a CTX-M
enzyme. For isolates with cefepime MICs >2 to <8 mg/L, use
of cefepime should be further guided by the ceftazidime MIC.
If the ceftazidime MIC remains in the susceptible range (<8
mg/L, predicting enzymes of pI 7.9, 8.4, or 8.8), cefepime
should not be used. If the ceftazidime MIC is >8 mg/L (pre-
dicting enzymes of pI 8.2), cefepime at appropriate doses has a
potential therapeutic role because most pI 8.2 enzymes rarely
elevate the cefepime MIC to >8 mg/L. 
In conclusion, outer membrane defects and the inoculum
effects (13) that may adversely elevate MIC values must still be
considered if cefepime is chosen as an alternative therapy
against ESBL-KP strains. This strategy of focused utilization of
a newer cephalosporin could reduce some selective pressures of
carbapenem use among ESBL-KP and thus minimize the
development of carbapenem-resistant strains. In addition, phe-
notypic characteristics appear to accurately differentiate two
important endemic and epidemic groups of ESBL types (CTX-
M series and SHV-like) in K. pneumoniae strains in Taiwan. 
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